Back to All Clinical Evidence
Detection of Bacterial Burden, Chronic Wounds
Novel Bacterial Auto-fluorescence Imaging Device Can Lead to more targeted debridement
Windy Cole, DPM; and Stacey Coe, BA, CCRP
Kent State University College of Podiatric Medicine, Independence, Ohio
Today’s Wound Clinic. April 2019.
References
Today’s Wound Clinic. April 2019.
Related Publications
![](https://moleculight.com/wp-content/uploads/2022/06/IWJ-logo.png)
![](https://moleculight.com/wp-content/uploads/2023/04/J-of-Racial-Ethnic-Health-Disparities-logo-Concise.jpg)
![](https://moleculight.com/wp-content/uploads/2023/03/Journal-of-Cutaneous-Immunology-and-Allergy_First-Impression-1000-x-723.png)
Detection of Bacterial Burden
![](https://moleculight.com/wp-content/uploads/2022/06/IWJ-logo.png)
![](https://moleculight.com/wp-content/uploads/2022/11/Capture.jpg)
Detection of Bacterial Burden
MolecuLight Headquarters
425 University Avenue
Suite 700
Toronto, ON M5G 1T6
Canada
US Address
MolecuLight Corp.
2403 Sidney Street,
Suite 209
Pittsburgh, PA 15203
T. +1 647-362-4684
North American Toll Free:
1-877-818-4360
F.+1 647-362-4730
E: info@moleculight.com
Sitemap
©2024
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.
Privacy Policy | Terms of Use | Software Privacy Policy
References
Today’s Wound Clinic. April 2019.